Ecosystem

At PRISM, we collaborate with academic, clinical, and industry leaders to drive innovation in proteomics, inflammatory responses, and precision health. These alliances enhance our research, enabling the development of advanced technologies and therapies that address global health challenges and improve patient care.

ECOSYSTEM

Collaborations

PRISM laboratory is a leading laboratory that boasts numerous collaborations at regional, national, and international levels. With a strong commitment to fostering scientific advancement, PRISM U1192 has established strategic partnerships with esteemed institutions and organizations around the globe. These collaborations span across diverse fields, ranging from cutting-edge research in medicine and biotechnology. Through these partnerships, PRISM has been able to leverage the expertise and resources of its collaborators, facilitating the exchange of knowledge, ideas, and innovative solutions to tackle biological and technological challenges of our time. With its extensive network of collaborations, it continues to contribute significantly to the global scientific community, promoting interdisciplinary research

Regional Network

National Network

International Network

ECOSYSTEM

Partners

ECOSYSTEM

LabCom

O’DREAMS

Oncological Driven Associated Mass Spectrometry

Equipe Mixte Laboratoire-Entreprise PRISM-OCR labellisée par la Région Hauts de France

In 2017, through the financial call of the regional Council Haut de France, PRISM and the company (OCR : Oncovet Clinical Research) have made a joined venture to lead a common laboratory named O’DREAMS. PIRSM and OCR are collaborating since the beginning of the SiricOncoLille, theu got in common an ANR, a Plan Cancer and applied in H2020 as well as in EuronanoMED. A pHD student is pay in part by OCR and the perosnnal of PRISM and OCR devoted to O’DREAMS are working together, in PRISM Laboartory (SN3). O’DREAMS is part of a clinical oncology theme through both technological and therapeutic developments of PRISM. Two lines of research will be developed i.e. The first axis is based on technological development which will allow the creation of non-invasive and real-time diagnostic instruments and is in line with the complementarity of the two entities. The first project is SPIDERMASS and the second one is entitled SNOOP-I. The second axis is focused on novel therapeutic developments in immunotherapy and oncoimmunology (MacBeth). All pre-clinical phases are performed on dog or cat patients who develop the same pathologies as humans. The preclinical phase in these animal patients will allow the faster development of clinical phases in humans. Rapid, non-invasive detection and prevention via the new tools developed by the unit will ultimately have a very important socio-economic impact for the region. The development of personalized treatment, validated in animal patients and then applied in humans, will guarantee better patient safety and more effective treatment. Together, these two areas will enable the O’DREAMS unit to be one of the leaders in the field of oncology at the regional, national and especially international levels.

Nouvel instrument : rapifleX^TM MALDI Tissuetyper^TM

IRP

IRP International Associated Laboratory (IAL) GHOST GLY : GHOST GlyCo Proteome

The GhostGly project will consist in the development of a tight collaboration to identify glycosylation on membrane ghost proteins and link these proteins to dysregulated intracellular signalling pathways in ovarian cancer of different phenotypes (mutation profile, type) compared to a control. The goal of GhostGly is to identify specific membrane ghost proteins with aberrant glycosylation as a potential target for immunotherapy. The GhostGly project aims to identify the protein interaction partners of selected AltProts to approach their function in ovarian cancer. We will focus our interest on membrane ghost proteins and will try to establish the nature of their glycoforms. Thus, finding specific membrane ghost proteins with altered glycosylation involved in ovarian cancer oncogenesis or EMT translation will be of great importance. GhostGly will give us the knowledge to find specific targets common to all ovarian cancer sub-types.

The four specific bjectives of GhostGly are therefore, 1) to identify interaction partners of AltProts by crosslinking MS (XL-MS), thereby assigning cellular functions to AltProts; 2) to identify the glycoforms of membrane ghost proteins in ovarian tumors; 3) to use targeted interactomics to identify target-specific PPIs and validate membrane AltProts functional interactome; and 4) to perform phenotypic studies of the selected AltProts by disturbing their expression. Involvement of the AltProts in resistance mechanisms will as well be studied by comparing the functional interactome network from untreated cells or cells upon treatment with chemotherapeutic drugs known to induce resistance. The obtained data will help to determine the oncogenesis of ovarian cancer by identifying new biomarkers and therapeutic targets.

Publications